Finance

Lists
Why is BBIO down 3,73%?
Dive Deeper
BBIO:NASDAQ
BridgeBio Pharma Inc
63,30 USD
-3,73%
(-2,45) 1D
63,04 USD
-0,41% (-0,26)
After hours
Closed: 13-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBIO...
Open
66,05 USD
High
66,05 USD
Low
62,94 USD
Mkt. cap
12,37 млд
Avg. vol.
2,72 млн
Volume
2,71 млн
52-wk high
93,42 USD
52-wk low
52,75 USD
EPS
-3,57 USD
Beta
0,97
Shares outstanding
195,49 млн
No. of employees
1 миң
Open
66,05 USD
High
66,05 USD
Low
62,94 USD
Mkt. cap
12,37 млд
Avg. vol.
2,72 млн
Volume
2,71 млн
52-wk high
93,42 USD
52-wk low
52,75 USD
EPS
-3,57 USD
Beta
0,97
Shares outstanding
195,49 млн
No. of employees
1 миң
News stories
From web sources and news partners
About BridgeBio Pharma Inc
CEONeil Kumar
Employees1 миң
Founded2015
HeadquartersПало Альто, Калифорния, Америка Кошмо Штаттары
Sector-
Websitebridgebio.com
Analyst ratings
Based on 17 analysts giving stock ratings to BBIO in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for BBIO in the last 3 months.
Highest
Current 63,30 USD
156,00 USD (+146,45%)
Average
111,38 USD (+75,96%)
Lowest
94,00 USD (+48,50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luca Issi
RBC Capital
Buy
Maintained
100,00 USD
+58%
10/08/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
106,00 USD
+67,5%
10/06/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
104,00 USD
+64,3%
10/06/2026
Eliana Merle
Barclays
Buy
Maintained
156,00 USD
+146,4%
10/07/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
10/06/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
120,00 USD
+89,6%
10/06/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
110,00 USD
+73,8%
09/24/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
130,00 USD
+105,4%
09/14/2026
Salim Syed
Mizuho Securities
Buy
Maintained
110,00 USD
+73,8%
08/31/2026
Andrew Tsai
Jefferies
Buy
Maintained
110,00 USD
+73,8%
08/31/2026
Biren Amin
Piper Sandler
Buy
Maintained
115,00 USD
+81,7%
08/31/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
110,00 USD
+73,8%
08/29/2026
Eric Joseph
Citi
Hold
Maintained
94,00 USD
+48,5%
08/12/2026
Anupam Rama
J.P. Morgan
Buy
Reiterated
111,00 USD
+75,4%
08/12/2026
Danielle Brill
Truist Financial
Buy
Maintained
107,00 USD
+69%
08/12/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
97,00 USD
+53,2%
08/11/2026
Derek Archila
Wells Fargo
Buy
Reiterated
102,00 USD
+61,1%
08/11/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
102,00 USD
+61,1%
08/11/2026
Tiago Fauth
Raymond James
Buy
Maintained
98,00 USD
+54,8%
06/17/2026
Martin Auster
Raymond James
Hold
Downgraded
-
-
05/26/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
05/19/2026
William Pickering
Bernstein
Buy
Reiterated
114,00 USD
+80,1%
05/08/2026
Paul Choi
Goldman Sachs
Buy
Maintained
116,00 USD
+83,3%
05/08/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
05/02/2026
Lisa Walter
RBC Capital
Buy
Initiated
100,00 USD
+58%
04/08/2026
Trevor Allred
Oppenheimer
Buy
Maintained
81,00 USD
+28%
02/25/2026
Last report
2026-ж., 10-авг.
Fiscal period
Q2 2026
-0,78 USD / -0,58 USD
-33,87%miss
Revenue / Est. (USD)
243,68 млн / 219,71 млн
+10,91%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
120,70 млн
154,18 млн
194,52 млн
243,68 млн
Cost of goods sold
6,56 млн
8,11 млн
9,94 млн
15,05 млн
Cost of revenue
6,56 млн
8,11 млн
9,94 млн
15,05 млн
Research and development expenses
112,87 млн
116,42 млн
126,64 млн
149,45 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
137,62 млн
158,08 млн
163,90 млн
186,26 млн
Operating expense
250,50 млн
274,50 млн
290,53 млн
335,71 млн
Total operating expenses
257,06 млн
282,61 млн
300,47 млн
350,76 млн
Operating income
-136,36 млн
-128,43 млн
-105,96 млн
-107,08 млн
Other non operating income
16,46 млн
11,82 млн
4,25 млн
5,59 млн
EBT including unusual items
-186,48 млн
-194,76 млн
-166,56 млн
-155,89 млн
EBT excluding unusual items
-177,64 млн
-183,62 млн
-166,56 млн
-155,89 млн
Income tax expense
-1,54 млн
-120,00 миң
-
-
Effective tax rate
0,83%
0,06%
-
-
Other operating expenses
-
-
-
-
Net income
-182,74 млн
-192,86 млн
-164,04 млн
-152,22 млн
Net profit margin
-151,40%
-125,09%
-84,33%
-62,47%
Earnings per share
-0,72
-0,94
-0,84
-0,78
Interest and investment income
6,24 млн
4,33 млн
6,25 млн
6,66 млн
Interest expense
-48,15 млн
-50,31 млн
-52,82 млн
-54,62 млн
Net interest expenses
-41,91 млн
-45,98 млн
-46,57 млн
-47,96 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-134,96 млн
-127,00 млн
-104,77 млн
-106,03 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору